A cost effectiveness analysis of adjuvant chemotherapy for node positive early breast cancer in South Africa: docetaxel, doxorubicin and cyclophosphamide (TAC) versus 5-fluorouracil, doxorubicin and cyclophosphamide (FAC)

被引：0
|
作者：
Rapoport, B. L. [1 ]
Moodley, S. D. [2 ]
Jacobs, C. [3 ]
Pienaar, R. [3 ]
Fourie, S.
Szpak, W. M.
机构：
[1] Med Oncol Ctr, Johannesburg, South Africa
[2] Univ Witwatersrand, Donald Gordon Med Ctr, Johannesburg, South Africa
[3] Panorama Mediclin, GVI Oncol Unit, Cape Town, South Africa
来源：
BREAST | 2007年 / 16卷
关键词：
D O I：
10.1016/S0960-9776(07)70240-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S64 / S64
页数：1
相关论文
共 50 条
  • [1] Cost–effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC)
    Sang Gyu Lee
    Young Geon Jee
    Hyun Chul Chung
    Sung-Bae Kim
    Jungsil Ro
    Young-Hyuck Im
    Seock-Ah Im
    Jae Hong Seo
    [J]. Breast Cancer Research and Treatment, 2009, 114 : 589 - 595
  • [2] Cost-effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC)
    Lee, Sang Gyu
    Jee, Young Geon
    Chung, Hyun Chul
    Kim, Sung-Bae
    Ro, Jungsil
    Im, Young-Hyuck
    Im, Seock-Ah
    Seo, Jae Hong
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2009, 114 (03) : 589 - 595
  • [3] Impact of adjuvant chemotherapy with docetaxel for early breast cancer:: Cost-effectiveness analysis (CEA) of a docetaxel, doxorubicin and cyclophosphamide regimen (TAC) versus 5-fluorouracil, doxorubicin and cyclophosphamide (FAC) in France
    Miadi-Fargier, H
    Le Pen, C
    Woronoff-Lemsi, MC
    Guastalla, JP
    Pivot, X
    Roché, H
    Pinguet, F
    Favier, B
    Gligorov, J
    Debrix, I
    Spielmann, M
    Antoine, EC
    Cadilhac, M
    De Pouvourville, GA
    [J]. VALUE IN HEALTH, 2005, 8 (06) : A36 - A37
  • [4] Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin and cyclophosphamide regimen (TAC) versus 5-fluorouracil, doxorubicin and cyclophosphamide (FAC) in early breast cancer at the Mexican Social Security Institute (IMSS) Mexico
    Valle-Solis, Aura A. Erazo
    Olivares, Guillermo
    Lazaro, Miguel
    Maurel, Frederique
    Robles, Jesus
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 107 - 107
  • [5] Quality of life and toxicity in breast cancer patients using adjuvant TAC (docetaxel, doxorubicin, cyclophosphamide), in comparison with FAC (doxorubicin, cyclophosphamide, 5-fluorouracil)
    Hatam, N.
    Ahmadloo, N.
    Kiadaliri, A. Ahmad
    Bastani, P.
    Askarian, M.
    [J]. ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2011, 284 (01) : 215 - 220
  • [6] Quality of life and toxicity in breast cancer patients using adjuvant TAC (docetaxel, doxorubicin, cyclophosphamide), in comparison with FAC (doxorubicin, cyclophosphamide, 5-fluorouracil)
    N. Hatam
    N. Ahmadloo
    A. Ahmad Kia Daliri
    P. Bastani
    M. Askarian
    [J]. Archives of Gynecology and Obstetrics, 2011, 284 : 215 - 220
  • [7] Doxorubicin and Cyclophosphamide versus Cyclophosphamide, Methotrexate, and 5-Fluorouracil as Adjuvant Chemotherapy in Breast Cancer
    Livi, L.
    Saieva, C.
    Borghesi, S.
    Cardillo, C. De Luca
    Scotti, V.
    Mangoni, M.
    Greto, D.
    Cataliotti, L.
    Paiar, F.
    Bianchi, S.
    Biti, G. P.
    [J]. JOURNAL OF CHEMOTHERAPY, 2009, 21 (05) : 558 - 565
  • [8] Comparison of Docetaxel, Doxorubicin and Cyclophosphamide (TAC) with 5-Fluorouracil, Doxorubicin and Cyclophosphamide (FAC) Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer: A Phase III Clinical Trial
    Omidvari, Shapour
    Hosseini, Sare
    Ashouri, Yaghoub
    Tahmasebi, Sedigheh
    Talei, Abdolrasoul
    Nasrolahi, Hamid
    Ahmadloo, Niloofar
    Ansari, Mansour
    Mosalaei, Ahmad
    Mohammadianpanah, Mohammad
    [J]. MIDDLE EAST JOURNAL OF CANCER, 2011, 2 (02) : 51 - 58
  • [9] Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects
    Au, Heather-Jane
    Golmohammadi, Kamran
    Younis, Tallal
    Verma, Shailendra
    Chia, Stephen
    Fassbender, Konrad
    Jacobs, Philip
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2009, 114 (03) : 579 - 587
  • [10] Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects
    Heather-Jane Au
    Kamran Golmohammadi
    Tallal Younis
    Shailendra Verma
    Stephen Chia
    Konrad Fassbender
    Philip Jacobs
    [J]. Breast Cancer Research and Treatment, 2009, 114 : 579 - 587
12345